Medicover account plan
International healthcare and diagnostic services
At a glance
Medicover is a Stockholm-listed healthcare and diagnostics group in Central and Eastern Europe, with FY2025 revenue of €2,378.1m and 49,409 co-workers.
Medicover is a healthcare services and diagnostics group founded in 1995 and listed on Nasdaq Stockholm since 2017, operating clinics, hospitals, dental and fertility clinics, gyms, laboratories and blood-drawing points. Its primary markets are Poland, Germany and Romania, with Poland 52% of FY2025 revenue, and 79% of group revenue comes from private pay (employer-funded plans and fee-for-service). FY2025 revenue was €2,378.1m (+13.7%, organic 12.7%), EBITDA €371.0m (15.6% margin) and profit for the year €72.7m, with 49,409 co-workers. In August 2026 it agreed to sell its Indian hospitals to funds managed by KKR. Celox Holding AB holds 56.0% of the votes.
Business units
Healthcare Services
69% of FY2025 revenue (€1,650.2m)Outpatient and inpatient care, dentistry, fertility, eye care, pharmacies, mental health and sports and wellness, sold as employer-funded plans, fee-for-service and public contracts; Poland is 70% of divisional revenue. In 2025 it ran 187 medical clinics, 41 hospitals, 110 dental clinics and 176 gyms, and EBITDA margin rose to 17.4%. Q3 2026 revenue was EUR 374.7 million (+6.0%), with sports and wellness the strongest contributor.
Diagnostic Services
31% of FY2025 revenue (€754.9m)Laboratory testing, genetic testing, CE-IVD kits and clinical trial services through 135 laboratories and 1,046 blood-drawing points in 15 countries, with brands such as Synevo and IMD Laboratory Berlin; Germany is 43% of divisional revenue. It ran 152.4 million tests in 2025 and integrated the SYNLAB businesses acquired in six countries. Q3 2026 revenue was EUR 203.8 million (+6.3%), with Germany and genetics softer.
Medicover Hospitals India
€203.6m revenue (FY2025)23 hospitals with 4,728 beds in four Indian states, 66.9% owned at end-2025. Now reported as a discontinued operation: Medicover agreed on 6 August 2026 to sell it to funds managed by KKR, with closing expected in Q4 2026.
Strategic priorities
- 2026-2028 financial targets
- Organic revenue above €3.25bn and adjusted organic EBITDA above €600m by 2028, leverage of 3.0x or less and a payout of up to 50%, unchanged until the India sale closes.
- Refocus on three European markets
- Proceeds of approximately EUR 0.74bn from the India sale are to accelerate strategy execution in Poland, Germany and Romania.
- Expand the service offering
- Grow speciality care (hospitals, dental, mental health, orthopaedics, sports and wellness) and advanced diagnostics; in Poland Medicover has consolidated only about 5% of the dental market and plans more hospitals.
- Operational excellence
- Procurement savings, a hub-and-spoke laboratory network on a proprietary laboratory information system, higher capacity utilisation and technology to cut doctors' administrative work.
- Digital differentiation
- Apps, telemedicine, digital triage and AI, including voice recognition and automated medical records, described as central to running and growing the business.
- Selective M&A and consolidation
- 86 acquisitions since the 2017 IPO; the CEO expects further consolidation in Poland and Romania as competitors reliant on public funds struggle.
Latest results
In Q3 2026 (continuing operations, India excluded), revenue rose 6.0% to EUR 570.8 million with organic growth of 8.0% and a 2.0% currency drag; EBIT grew 22.0% to EUR 49.3 million at an 8.6% margin, and net profit was EUR 24.8 million. It was the seventh consecutive quarter of year-on-year margin improvement. Over nine months, revenue was EUR 1,721.6 million (+6.4%, organic +8.5%). Leverage fell to 2.7x from 3.1x at end 2025, and a new EUR 450.0 million RCF was signed. Management flags near-term softness in public reimbursement, a German genetics reform from October 2026, and slower B2B membership.
Investments and deals
- SYNLAB businesses acquisition
- Completed in 2025 in Romania, Turkey, Cyprus, Slovenia, Croatia and North Macedonia: 30 laboratories, 100 blood-drawing points and over 600 professionals.
- CityFit gym chain
- Acquired in 2025 in Poland: 26 clubs and nearly 130,000 active members; 16 new fitness facilities opened in 2026 so far, with openings set to accelerate.
- Sale of Medicover Hospitals India
- A EUR 1.2 billion transaction with funds managed by KKR announced 6 August 2026; Medicover's 66.1% stake brings about EUR 740 million and should leave it debt-free.
- Capex and network reshaping
- Capex in PP&E and intangibles was €158.1m in 2025; full-year 2026 capex is guided at 6-6.5% of revenue, and 118 facilities were closed while over 140 opened in twelve months.
- Medicover Genetics MRD test
- A blood-based minimal residual disease test for lung cancer recurrence, launched in 2026, detects issues 7.4 months earlier than traditional methods.
Challenges and risks
- Public reimbursement cuts
- German laboratory reimbursement fell from 1 January 2025, a German genetics reform took effect in October 2026, and Romania brought caps and tariff cuts in public healthcare.
- Medical workforce shortage
- Rated a High risk in the 2025 risk register; inflation-driven medical salary increases weigh on Polish inpatient margins.
- Geopolitical and data risks
- Armed conflict (Ukraine) and data loss or breach are the other two risks rated High.
- Slower B2B membership
- Members fell to 1,487K in Q3 2026 from 1,549K, mainly in Romania, after pricing decisions and slower employer hiring.
What leadership says
“maybe we kept our prices a little bit too high for a little bit too long, and we need to repurpose or make adjustments, which we've done.”
“The Indian divestment brings us EUR 740 million, and we will focus that money on our core countries.”
“First and foremost, you need scale in healthcare. That's why our number one strategic priority remains growth.”
“We've all seen doctors typing with one finger”
Where a supplier can help
- Clinical documentation and AI
- The efficiency priority of freeing doctors from administrative work, with voice recognition and automated medical records, opens room for clinical AI and documentation tools.
- Laboratory automation
- Consolidation and automation are Medicover's answer to German reimbursement cuts, a fit for lab automation, LIS and logistics suppliers.
- Fit-out for new gyms, clinics and hospitals
- Accelerated gym openings, planned Polish hospitals and over 140 new facilities in twelve months create demand for equipment, construction and facility services.
- Post-acquisition integration
- The SYNLAB integration and expected further consolidation, funded by the India proceeds, call for integration, IT migration and procurement support.
- Workforce and data security
- Workforce shortage and data breach risks, both rated High, point to recruiting, retention and cyber security offerings.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Medicover?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Medicover Annual Report 2025
- Medicover is a Stockholm-listed (Nasdaq Stockholm since 2017) healthcare and diagnostics group founded in 1995, operating in Central and Eastern Europe and India through two divisions: Healthcare Services (69% of revenue) and Diagnostic Services (31%).
- FY2025 revenue was €2,378.1m (+13.7%, organic growth 12.7%); EBITDA €371.0m (15.6% margin, up from 13.6%); operating profit €155.7m (€70.3m); profit for the year €72.7m (€14.6m); 49,409 co-workers.
- Revenue by country: Poland 52%, Germany 16%, Romania 13%, India 9%, Other 10%; 79% of group revenue comes from private pay, reflecting low reliance on public funding.
- 2023-2025 financial targets were exceeded (organic revenue €2.3bn vs >€2.2bn target; adjusted organic EBITDA €369m vs >€350m; leverage 3.1x vs ≤3.5x). New 2026-2028 targets: organic revenue >€3.25bn, adjusted organic EBITDA >€600m, leverage ≤3.0x, dividend payout up to 50%.
- 2025 brought the two largest acquisitions in Medicover's history: SYNLAB's businesses in Romania, Turkey, Cyprus, Slovenia, Croatia and North Macedonia (30 laboratories, 100 blood-drawing points) and the CityFit gym chain in Poland (26 locations in 17 cities).
- John Stubbington (with Medicover since 2010, previously leading Healthcare Services) became CEO on 1 May 2025, succeeding Fredrik Rågmark after 25 years; Anand Patel is CFO.
- Strategy: three core strategies (retain and grow the customer base, expand the service offering, pursue operational excellence) plus two supporting strategies (digital differentiation, selective M&A); 86 acquisitions since the 2017 IPO.
- Key risks rated High: armed conflict and geopolitical risk (Ukraine, increasing), data loss or breach, and medical workforce shortage; German laboratory reimbursement cuts from 1 January 2025 were managed through consolidation and automation.
- Medicover Genetics' ctDNA-based minimal residual disease (MRD) assay for lung cancer showed positive interim results in the DART study, with commercialisation planned for H2 2026.
- Interim report July-September 2026
- Q3 2026 (continuing operations, Indian hospitals now reported as discontinued): revenue EUR 570.8m (+6.0%, organic +8.0%, FX -2.0%); EBIT EUR 49.3m (+22.0%, margin 8.6% vs 7.5%); EBITDA EUR 99.3m (17.4% margin); net profit EUR 24.8m.
- Medicover agreed on 6 August to sell Medicover Hospitals India to funds managed by KKR; its 66.1% stake brings gross cash proceeds of approximately EUR 0.74bn, with closing expected in Q4 2026, to be used for strategy execution in Poland, Germany and Romania.
- Nine months 2026: revenue EUR 1,721.6m (+6.4%, organic +8.5%); EBIT EUR 145.0m (8.4% margin); EBITDA EUR 294.5m (17.1%).
- Healthcare Services Q3: revenue EUR 374.7m (+6.0%, organic +8.0%, of which price about 6.3pp), EBITDA margin 19.8%; 16 new fitness facilities opened in 2026; members 1,487K (1,549K), falling in Romania; over 4.1 million ongoing customer relationships.
- Diagnostic Services Q3: revenue EUR 203.8m (+6.3%, organic +8.5%), EBITDA margin 18.5%; 40.2 million tests (+5.3%); FFS is 74% of divisional revenue; Germany and genetics softer.
- A German genetics reimbursement reform effective October 2026 is expected to lower margin contribution; the CEO expects "continued softness in public reimbursement" near term.
- Leverage 2.7x (3.1x at end 2025); 118 facilities closed and over 140 opened in the last twelve months; 2026-2028 targets (organic revenue >EUR 3.25bn, adjusted organic EBITDA >EUR 600m, leverage ≤3.0x) unchanged until the India deal completes.
- Medicover Q3 2026 earnings call transcript
- CEO John Stubbington and CFO Anand Patel presented Q3 2026: 8% organic growth on continuing operations and a seventh consecutive quarter of year-on-year margin improvement; EBIT up 22%.
- The India hospital sale (transaction of EUR 1.2 billion, Medicover's 66.1% share about EUR 740 million) is a complete exit; Stubbington says the money will go to "our core countries" and Medicover should be debt-free after closing.
- Near-term headwinds flagged: public reimbursement changes, 118 closed locations, slower B2B membership (Romania), and a German genetics reform he calls "quite brutal" on face value, which "will hit us" but should be managed over about four quarters.
- Funded growth in Poland had relied on price; Stubbington admits "maybe we kept our prices a little bit too high for a little bit too long" and says the B2B pipeline is now stronger.
- Sports and wellness in Poland is accretive and growing faster than core Healthcare Services; openings will accelerate in Q4 and beyond, with Poland still behind Western Europe in gyms per head.
- Medicover launched its blood-based MRD test detecting lung cancer recurrence, which picks up issues 7.4 months earlier than traditional methods.
- With funds available and competitors squeezed by rates and government changes, he expects "further consolidation"; CFO guides full-year capex at 6-6.5% of revenue and leverage fell to 2.7x.
- Medicover Q2 2026 earnings call transcript
- Q2 2026 (before India was reclassified): revenue EUR 640.4 million, organic growth 11.8%, adjusted EBITDA EUR 109.2 million at a 17.1% margin, the sixth consecutive quarter of margin improvement; leverage 2.9x.
- India hospitals grew 23.1% in euros and 39.6% in local currency; Stubbington said the Indian IPO "still very much is an option" while the company evaluated inbound interest (KKR talks had been reported in June).
- Healthcare Services organic growth 12.2% (price 5.2%); funded business in Poland growing again; Romanian membership cut after "harsher decisions" on unprofitable contracts.
- Diagnostics organic growth 10.9% with margin up 110 basis points; synergies from the two 2025 acquisitions, "our largest in our history", are coming through.
- Romania's political instability brought caps and tariff cuts in public healthcare; Stubbington expects patients to switch to fee-for-service: "Usually that creates opportunity for us."
- On Polish government plans affecting doctors' pay and public procedures: "This is business as usual to us."
- CFO Anand Patel: EBIT EUR 51.2 million at an 8% margin, ROIC 13.6% (9.3%), capex about 6% of revenue for the year; 2028 targets still expected to be achieved.
- Medicover's Scaling Strategy: Growth, Efficiency and Customer Satisfaction (WBJ interview with John Stubbington)
- Interview in the Warsaw Business Journal with John Stubbington shortly after he became CEO; he joined Medicover in 2010 after 17 years at Bupa to look after its insurance company with one employee.
- His side of the business grew from around €100 million to approximately €2.4-2.5 billion; Medicover has added roughly 700,000 square meters of care space and is approaching a million square meters.
- Three strategic priorities for the next decade: growth (scale lets Medicover specialise), efficiency (empowering customers, freeing doctors from administrative work) and satisfaction (around 600,000 surveys a year).
- Medicover is the largest dental provider in Poland but has consolidated only about 5% of a fragmented market; it both builds greenfield sites and acquires.
- Growth areas in Poland: gyms and fitness (smaller operators, no large chains left to buy) and hospitals (11 in Poland today, more planned through acquisitions or new builds).
- Government-funded work is a relatively small share; "The vast majority of what we do is private pay".
Questions about Medicover
What does Medicover do?
Medicover runs healthcare services (clinics, hospitals, dental, fertility, gyms) and diagnostic laboratories, mainly in Poland, Germany and Romania, funded mostly by private pay.
What is Medicover's revenue?
FY2025 revenue was €2,378.1m, up 13.7%, with EBITDA of €371.0m. Q3 2026 revenue from continuing operations was EUR 570.8 million.
How many employees does Medicover have?
49,409 co-workers at end of 2025.
Who leads Medicover?
John Stubbington has been CEO since 1 May 2025, Anand Patel is CFO, and Fredrik Stenmo chairs the board.
Why is Medicover selling its Indian hospitals?
The sale to funds managed by KKR brings about EUR 740 million for Medicover's 66.1% stake, to be focused on Poland, Germany and Romania.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)